Patient's Perception of Treatment Outcome With Darifenacin by Patients With Overactive Bladder
Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
This study will evaluate safety, efficacy and patient's perception of outcome after treatment
with darifenacin (7.5 mg once daily (o.d.) with voluntary increase up to 15 mg o.d.) in
patients with OAB who are dissatisfied with prior oxybutynin extended release (ER) or
tolterodine extended release (ER) therapy.